TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas.

Background: Myeloid cells comprise up to 50% of the total tumor mass in glioblastoma (GBM) and have been implicated in promoting tumor progression and immunosuppression. Modulating the response of myeloid cells to the tumor has emerged as a promising new approach for cancer treatment. In this regard, we focus on the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which has recently emerged as a novel immune modulator in peripheral tumors.

TREM2 mediates MHCII-associated CD4 T cell response against gliomas.

Triggering receptor expressed on myeloid cells 2 (TREM2) was recently highlighted as a novel immune suppressive marker in peripheral tumors. The aim of this study was to characterize expression in gliomas and investigate its contribution in glioma progression by using mouse line. Our results showed that higher expression was correlated with poor prognosis in glioma patients.